## **Regulatory Panel Session**



# "What are the Regulatory Challenges and Needs?"



#### **Moderator:**

Dr. Aliza Thompson (FDA)

### **Panelists:**

Dr. Norman Stockbridge (FDA)

Dr. Shashi Amur (FDA)

Dr. Ameeta Parekh (FDA)

Dr. Thorsten Vetter (EMA)

### What are the Regulatory Challenges and Needs?



- 1. Evidentiary standards for biomarker qualification- What are they? What should they be?
- 2. Timelines for biomarker qualification- Why does it take so long to qualify a biomarker? Is Consortium "burn out" an issue and if so, how have we tried to address it?
- 3. Resource constraints- How should we decide which biomarker submissions to accept? Should we be devoting resources to qualifying prognostic biomarkers?



## **Regulatory Panel Session**



# "What are the Regulatory Challenges and Needs?"



### **Moderator:**

Dr. Aliza Thompson (FDA)

### **Panelists:**

Dr. Norman Stockbridge (FDA)

Dr. Shashi Amur (FDA)

Dr. Ameeta Parekh (FDA)

Dr. Thorsten Vetter (EMA)